Table 2.
Age-stratified prevalence of moderate-to-severe acne in transgender adults and association with current testosterone use in transmasculine adults
| Age | Moderate-to-severe acne | All | TM | TF | P |
|---|---|---|---|---|---|
| 18–29 | No | 127 (58.5) | 83 (56.1) | 44 (63.8) | 0.004 |
| Yes - currently | 38 (17.5) | 35 (23.7) | 3 (4.4) | ||
| Yes - in the past | 31 (14.3) | 18 (12.2) | 13 (18.8) | ||
| Missing | 21 (9.7) | 12 (8.1) | 9 (13.0) | ||
| 30–39 | No | 105 (67.3) | 67 (64.4) | 38 (73.1) | 0.35 |
| Yes - currently | 5 (3.2) | 5 (4.8) | 0 (0) | ||
| Yes - in the past | 27 (17.3) | 20 (19.2) | 7 (13.5) | ||
| Missing | 19 (12.2) | 12 (11.5) | 7 (13.5) | ||
| 40–54 | No | 116 (69.1) | 41 (59.4) | 75 (75.8) | 0.004 |
| Yes - currently | 7 (4.2) | 7 (10.1) | 0 (0) | ||
| Yes - in the past | 21 (12.5) | 9 (13.0) | 12 (12.1) | ||
| Missing | 24 (14.3) | 12 (17.4) | 12 (12.1) | ||
| ≥55 | No | 101 (65.2) | 17 (68.0) | 84 (64.6) | 0.84a |
| Yes - currently | 0 (0) | 0 (0) | 0 (0) | ||
| Yes - in the past | 16 (10.3) | 3 (12.0) | 13 (10.0) | ||
| Missing | 38 (24.5) | 5 (20.0) | 33 (25.4) | ||
| N (%) | Current Moderate-to-Severe Acne in TM | Age-adjusted PR (95% CI) | |||
| Yes | No | ||||
| Current testosterone use | |||||
| No | 58 (16.8) | 6 (10.3) | 52 (89.7) | [reference] | |
| Yes | 288 (83.2) | 41 (14.2) | 247 (85.8) | 1.26 (0.58–2.73) | |
| Route of testosterone administration | |||||
| Injection alone | 244 (84.7) | 35 (14.3) | 209 (85.7) | [reference] | |
| Other regimensb | 44 (15.3) | 6 (13.6) | 38 (86.4) | 1.08 (0.49–2.40) | |
TM, transmasculine; TF, transfeminine; PR, prevalence ratio; N/A, not applicable
a
Fisher’s exact test for patients ≥55 years old excluded the zero row since there were no patients reporting current moderate-to-severe acne.
b
Other regimens include testosterone gel, patch, and/or oral testosterone alone or in combination with testosterone injection